1. Home
  2. BEAM vs KLIC Comparison

BEAM vs KLIC Comparison

Compare BEAM & KLIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.68

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Kulicke and Soffa Industries Inc.

KLIC

Kulicke and Soffa Industries Inc.

HOLD

Current Price

$46.72

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
KLIC
Founded
2017
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
KLIC
Price
$26.68
$46.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
3
Target Price
$48.09
$46.67
AVG Volume (30 Days)
2.0M
766.4K
Earning Date
11-04-2025
02-03-2026
Dividend Yield
N/A
1.71%
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
$55,701,000.00
$654,081,000.00
Revenue This Year
N/A
$20.77
Revenue Next Year
$26.52
$8.23
P/E Ratio
N/A
$11,819.78
Revenue Growth
N/A
N/A
52 Week Low
$13.53
$26.63
52 Week High
$35.25
$52.08

Technical Indicators

Market Signals
Indicator
BEAM
KLIC
Relative Strength Index (RSI) 55.81 58.15
Support Level $25.86 $47.50
Resistance Level $28.10 $49.69
Average True Range (ATR) 1.56 1.65
MACD 0.17 0.02
Stochastic Oscillator 57.39 45.14

Price Performance

Historical Comparison
BEAM
KLIC

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About KLIC Kulicke and Soffa Industries Inc.

Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.

Share on Social Networks: